Drug-resistant tuberculosis (TB) is estimated to cause 13% of all antimicrobial resistance-
attributable deaths worldwide and is driven by both ongoing resistance acquisition and …

Tuberculosis (TB) drug discovery and development has undergone nothing short of a
revolution over the past 20 years. Successful public–private partnerships and sustained …

Abstract In December 2022 World Health Organization released a new treatment for
multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) guideline. The main …

Executive summary The 2019 Lancet Commission on Tuberculosis laid out an optimistic
vision for how to build a tuberculosis-free world through smart investments based on sound …

Background Around 500 000 people worldwide develop rifampicin-resistant tuberculosis
each year. The proportion of successful treatment outcomes remains low and new …

Background Tuberculosis (TB) is a global health challenge and one of the leading causes of
death worldwide. In the last decade, the TB treatment landscape has dramatically changed …

Tuberculosis (TB) elimination and pre-elimination, with thresholds of 1 and 10 incident
cases per million population, respectively, were considered achievable for low TB incidence …

Background The current tuberculosis (TB) drug development pipeline is being re-populated
with candidates, including nitroimidazoles such as pretomanid, that exhibit a potential to …

English Language (EL) is a core subject in schools, and success in it is a part of the
requirements for certification and educational advancement. However, evidence has shown …

Background Effectiveness, safety, tolerability, and adherence are critical considerations in
shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include …